Livagen

What is Livagen?

Livagen is a synthetic tetrapeptide consisting of lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala, or KEDA), developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. It is one of the most mechanistically characterized bioregulator peptides, with direct evidence of chromatin decondensation in human lymphocytes from elderly subjects. Livagen targets the liver, gastrointestinal tract, and immune system, and shares its first three amino acids with Vesugen (KED), differing only by the C-terminal alanine. With 9 PubMed-indexed publications, it has some of the strongest preclinical evidence for the chromatin-remodeling mechanism that underpins the entire Khavinson bioregulator theory.

What Livagen Is Investigated For

Livagen (KEDA) is studied within the Khavinson bioregulator framework for hepatoprotection, digestive enzyme restoration in aging, and immune cell reactivation — with its defining claim being chromatin decondensation and reactivation of age-silenced genes in lymphocytes from elderly donors. The strongest evidence is preclinical and mechanistic: direct ex vivo visualization of heterochromatin decondensation and ribosomal gene activation in aged human lymphocytes (PMID 12533768, 15085253) makes Livagen arguably the best-characterized Khavinson peptide in terms of its proposed epigenetic mechanism. The honest caveats are substantial — no human clinical trials of any kind, no independent Western replication of the chromatin-decondensation finding, no human pharmacokinetic characterization, and a published footprint dominated entirely by the originating Khavinson-affiliated group in primarily Russian-language literature. Hepatoprotective and immunomodulatory claims in consumer-facing marketing significantly exceed what the rodent models and ex vivo studies support, and Livagen should not be considered a treatment for diagnosed hepatitis, liver disease, or immunologic conditions.

History & Discovery

Livagen comes out of the same Khavinson bioregulator program that produced Epithalon, Vesugen, and the broader Cytogen / Cytomax peptide series at the St. Petersburg Institute of Bioregulation and Gerontology. The starting point was a porcine liver tissue extract from which the Khavinson group claimed to isolate a defining short-peptide active fraction; the synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA) was then proposed as the chemically defined Cytogen counterpart. Among the bioregulators, Livagen is unusual in that the originating group reported direct cytogenetic evidence — chromatin decondensation in lymphocytes from elderly donors — that is at least concrete enough to point to as a candidate mechanism for the broader 'short peptides reactivate age-silenced genes' framework. That said, the indexed footprint remains small and overwhelmingly originates from Khavinson-affiliated investigators in Russian-language literature. Independent replication of the chromatin-decondensation finding by Western cytogenetics laboratories has not occurred, and there are no human clinical trials of Livagen as an interventional agent. The peptide reaches Western users almost exclusively through the consumer Khavinson Peptides oral capsule line and through research-chemical lyophilized vials, neither of which represents validated therapeutic use.

How It Works

Livagen works by reopening tightly packed DNA in aging cells. As we age, portions of our DNA become locked down and the genes there stop working. Livagen has been shown to reverse this process — specifically in immune cells and liver cells — reactivating genes involved in protein production, immune function, and digestive enzyme activity.

Livagen (Lys-Glu-Asp-Ala) induces deheterochromatinization — the conversion of tightly packed heterochromatin back to transcriptionally active euchromatin. In lymphocytes from elderly subjects (ages 75-88), it activated ribosomal genes, decondensed pericentromeric structural heterochromatin, and released genes repressed by age-related condensation, specifically affecting heterochromatic regions of chromosomes 1 and 9. In hepatocyte cultures, it enhanced protein synthesis rhythm and intensity, with stronger effects in aged cells. Oral administration in aged rats restored digestive enzyme activity (dipeptidases) toward young-animal levels, suggesting functional restoration of GI tissue. It resists degradation by small intestinal peptidases, supporting oral bioavailability. A 2020 review confirmed hepatoprotective and immunomodulatory effects, normalizing antioxidant markers and restoring liver function in hepatitis models, with strongest effects in aging organisms.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Livagen:

• 01Independent Western replication of the chromatin-decondensation finding in human lymphocytes — the foundational mechanism for Livagen's most distinctive claim has not been independently verified outside the originating research group.
• 02Human pharmacokinetics — oral and parenteral bioavailability of the KEDA tetrapeptide in humans is uncharacterized, despite oral capsules being the dominant commercial form.
• 03Tissue-specificity mechanism — why KEDA targets liver/immune tissue while the near-identical KED targets vascular endothelium has no convincing molecular explanation.
• 04Blinded randomized controlled trials in any liver or immune indication — the published evidence is dominated by ex vivo human-tissue work and rodent models, not human clinical endpoints.
• 05Long-term safety of repeated chromatin-reactivation cycles — what happens to gene expression and oncogene-suppressor balance over years of repeated 10-day courses is unknown.
• 06Comparative efficacy versus standard hepatoprotective interventions (ursodiol, N-acetylcysteine, lifestyle management) — no head-to-head data exists.

Forms & Administration

Livagen is available in capsule and injectable formats. Oral bioavailability is supported by its resistance to intestinal peptidase degradation. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Livagen is not FDA-approved for any indication. Hepatoprotective and immunomodulatory claims significantly exceed what controlled clinical evidence supports. It should not substitute for evaluation of liver disease, hepatitis, or immunosuppression by a qualified clinician.

Timeline of Effects

Common Questions

Who Livagen Is NOT For

Drug & Supplement Interactions

There are no documented clinical drug interactions for Livagen because there are no human pharmacovigilance studies of any meaningful scale. What follows is theoretical. The most plausible mechanistic concerns are with anti-cancer chemotherapy and radiation, where any agent claimed to broadly reactivate transcription and ribosomal activity in aged cells is mechanistically working against the intent of treatment. A second concern applies to immunosuppressive regimens (post-transplant tacrolimus or cyclosporine, biologics for autoimmune disease) where claimed lymphocyte reactivation is similarly counter to therapeutic intent. Hepatotoxic medications (high-dose acetaminophen, methotrexate, certain antiretrovirals) sit in a category where Livagen is sometimes described as 'protective' on the strength of rodent hepatitis-model data, but that protective claim has not been demonstrated in humans and should not be assumed clinically. Patients on any regular medication should disclose Livagen use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions